[go: up one dir, main page]

MX2010001449A - Bromhidrato de bupropion y aplicaciones terapeuticas. - Google Patents

Bromhidrato de bupropion y aplicaciones terapeuticas.

Info

Publication number
MX2010001449A
MX2010001449A MX2010001449A MX2010001449A MX2010001449A MX 2010001449 A MX2010001449 A MX 2010001449A MX 2010001449 A MX2010001449 A MX 2010001449A MX 2010001449 A MX2010001449 A MX 2010001449A MX 2010001449 A MX2010001449 A MX 2010001449A
Authority
MX
Mexico
Prior art keywords
bupropion hydrobromide
therapeutic applications
bupropion
hydrobromide
treatment
Prior art date
Application number
MX2010001449A
Other languages
English (en)
Inventor
Robert Parry Williams
Peter Harris Silverstone
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39225245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010001449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Publication of MX2010001449A publication Critical patent/MX2010001449A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen formulaciones de bromhidrato de bupropion, así como también su uso para el tratamiento de afecciones.
MX2010001449A 2007-08-07 2008-08-06 Bromhidrato de bupropion y aplicaciones terapeuticas. MX2010001449A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/834,848 US7671094B2 (en) 2005-06-27 2007-08-07 Bupropion hydrobromide and therapeutic applications
PCT/EP2008/060361 WO2009019294A2 (en) 2007-08-07 2008-08-06 Bupropion hydrobromide and therapeutic applications

Publications (1)

Publication Number Publication Date
MX2010001449A true MX2010001449A (es) 2010-03-10

Family

ID=39225245

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001449A MX2010001449A (es) 2007-08-07 2008-08-06 Bromhidrato de bupropion y aplicaciones terapeuticas.

Country Status (17)

Country Link
US (2) US7671094B2 (es)
EP (1) EP2185139A2 (es)
JP (1) JP2010535740A (es)
KR (1) KR20100055402A (es)
CN (1) CN101784266B (es)
AU (1) AU2008285660A1 (es)
CA (1) CA2700733A1 (es)
CO (1) CO6251360A2 (es)
CR (1) CR11259A (es)
EC (1) ECSP109923A (es)
MX (1) MX2010001449A (es)
NI (1) NI201000015A (es)
NZ (1) NZ582925A (es)
RU (1) RU2485943C2 (es)
SG (1) SG183695A1 (es)
WO (1) WO2009019294A2 (es)
ZA (1) ZA201000425B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
CA2476201C (en) * 2002-02-21 2009-09-01 Biovail Laboratories Incorporated Modified release formulations of at least one form of tramadol
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
WO2007063946A1 (ja) * 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
US8349900B2 (en) * 2008-08-07 2013-01-08 Valeant International Bermuda Bupropion hydrobromide polymorphs
CN101811975B (zh) * 2009-04-20 2013-01-16 浙江普洛医药科技有限公司 氢溴酸安非他酮的多晶型物及其制备方法
TR201001862A1 (tr) * 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
WO2016140906A1 (en) * 2015-03-02 2016-09-09 Graphene 3D Lab Inc. Thermoplastic composites comprising water-soluble peo graft polymers useful for 3-dimensional additive manufacturing
US11911510B2 (en) * 2017-08-31 2024-02-27 Purdue Pharma L.P Pharmaceutical dosage forms
CN117693335A (zh) * 2021-05-11 2024-03-12 罗斯研究中心有限责任公司 组合治疗方法
AU2023366929A1 (en) * 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil
US12083080B2 (en) 2023-12-04 2024-09-10 Richard Louis Price Therapeutic methods using bupropion hydrobromide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2318960A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6033686A (en) 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6780871B2 (en) 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
NZ544281A (en) * 2003-08-08 2008-07-31 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
WO2005120523A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7884136B2 (en) * 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
EP1954257A4 (en) 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US8349900B2 (en) * 2008-08-07 2013-01-08 Valeant International Bermuda Bupropion hydrobromide polymorphs

Also Published As

Publication number Publication date
CO6251360A2 (es) 2011-02-21
NI201000015A (es) 2011-03-23
WO2009019294A2 (en) 2009-02-12
WO2009019294A9 (en) 2009-06-11
EP2185139A2 (en) 2010-05-19
SG183695A1 (en) 2012-09-27
AU2008285660A1 (en) 2009-02-12
KR20100055402A (ko) 2010-05-26
RU2485943C2 (ru) 2013-06-27
CN101784266B (zh) 2012-07-18
US8354453B2 (en) 2013-01-15
ZA201000425B (en) 2011-04-28
CR11259A (es) 2010-08-05
US20100104639A1 (en) 2010-04-29
NZ582925A (en) 2012-09-28
CN101784266A (zh) 2010-07-21
WO2009019294A3 (en) 2009-08-13
JP2010535740A (ja) 2010-11-25
CA2700733A1 (en) 2009-02-12
HK1142811A1 (en) 2010-12-17
US20080075774A1 (en) 2008-03-27
US7671094B2 (en) 2010-03-02
RU2010107843A (ru) 2011-09-20
ECSP109923A (es) 2010-03-31

Similar Documents

Publication Publication Date Title
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
WO2009056550A3 (en) Bupropion hydrobromide and therapeutic applications
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
PH12011502704A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
MX2010003258A (es) Utilizacion de un nuevo agente natural en composiciones cosmeticas.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
IL201479A (en) Use of tapentadol for the preparation of pain medication
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2011007930A (es) Conjugados de insulina cristalina.
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
PH12014500053A1 (en) Proteasome inhibitors
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2011011109A (es) Formulaciones orales de bendamustina.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MY150931A (en) Substituted oxazolidinones and their use
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
IL194353A0 (en) Lysobactin amides

Legal Events

Date Code Title Description
FA Abandonment or withdrawal